Relapsing multiple sclerosis (RMS) is the most common phenotype of multiple sclerosis (MS) characterized by episodes of transient exacerbations of neurological disability.1 Ozanimod is a sphingosine 1-phosphate (S1P) receptor 1 and 5 modulator.2 Its effect on RMS have been studied in multiple clinic

Recent studies have demonstrated that anti-amyloid monoclonal antibodies (mAbs) can attenuate cognitive and functional deterioration in patients with early symptomatic Alzheimer’s disease (AD).¹  One of these mAbs, lecanemab, a humanized immunoglobulin G1 (IgG1) mAb, was verified to diminish amyloid markers and decelerate cognition deterioration in early AD patients after 18 months of treatment in a double-blind, phase 3 trial named CLARITY-AD.² These promising results indicated that anti-amyloid mAbs could be incorporated into real-life clinical care for early AD patients.¹ To expedite their incorporation in clinical practice, the American Academy of Neurology (AAN) published expert consensus guidance on how to optimize anti-amyloid mAbs AD treatment.¹

For decades, migraine prevention relied on nonspecific, off-label drugs, often lacking large-scale clinical trials to confirm their efficacy, safety, or tolerability.^1-3 This has resulted in high discontinuation rates.^2,3 However, the introduction of calcitonin gene-related peptide (CGRP) pathway-targeting therapies has revolutionized migraine management.³ At a recent symposium, Dr. Sait Ashina, Director of the BIDMC Comprehensive Headache Center and Assistant Professor at Harvard Medical School in the United States (US), discussed how beyond randomized controlled trials (RCTs), the 5-year real-world evidence (RWE) data further demonstrate the utility of CGRP pathway-targeting therapies in the evolution of migraine prevention.